You started the medication, you followed the plan, and the scale has barely moved. Somewhere in the weeks that follow, the question arrives, and it rarely arrives gently. It usually sounds like: is this working for me at all, or am I one of the people it does not work for?
This article is about that question. What the trials and clinicians actually call a weaker response, what is known about why responses differ, the calendar check that resolves a surprising number of cases before any of that matters, and what a record can contribute to the conversation with a prescriber, which is the only place the question gets answered for real.
First, the calendar check
Before the terminology, one thing deserves prominence, because a large share of the people who believe they are not responding are simply early. GLP-1 medications climb a ladder. Starting doses are not weight-loss doses; they are the beginning of a titration that takes months, with steps typically every few weeks. And after each step up, medication levels keep building for about a month before they settle where they are going.
Put those together and the implication is blunt: judging your response before you have reached the maintenance dose your prescriber prescribed is usually too early. It is like reading the first third of a book and asking why the plot has not resolved. If you are six weeks into a schedule whose ladder takes months to climb, the honest description of where you are is not "not responding." It is "in progress," and those are different things. How the ladders work, medication by medication, is laid out in GLP-1 Titration Schedules Explained, Medication by Medication, and why levels keep rising for weeks after each dose is the subject of Semaglutide Half-Life: Understanding Your Medication Level.
It helps to know what the early weeks of a ladder are actually for. The low starting steps exist largely so the digestive system can meet the medication gradually, which is why the first weeks often feel like side effects without much payoff: the dose is doing its tutoring, not yet its heaviest work. The payoff portion of the schedule is the part that comes after, at the doses reached later, and that is also the only part where the response question has a fair hearing. Patience here is not stoicism; it is arithmetic.
The calendar check is also why a log beats memory here. "It has been a while and nothing is happening" is a feeling. "I am in week 7, on step 2 of 5, having reached this step three weeks ago" is a fact, and facts are what appointments run on.
What the trials call a weaker response
Now the terminology. When clinicians and researchers talk about response to GLP-1 medications, they commonly use a working line: losing less than 5 percent of starting body weight. Below that line, the response gets described as weaker. Trials of these medications consistently include a minority of participants who land there, which is to say, in every study there are some people for whom the medication does less.
We will deliberately stop there. How many people fall below the line is the kind of number that gets repeated with false confidence, and it varies by medication, dose, duration and population. What matters to you is narrower: the line exists, clinicians use it, and where you sit relative to it is a determination for the person prescribing, not for an article, an app, or a bathroom scale.
One more distinction, because the internet blurs it constantly. A weaker response from the start is a different thing from a plateau, which is loss that happened and then stalled. Both are discouraging in similar ways, and both are ordinary physiology or pharmacology rather than failure, but they are not the same situation and they do not lead to the same conversation. The stall-after-loss story is covered in Hit a Plateau on a GLP-1? What Your Data Can Tell You.
GLP 1 Tracker AppThe dose ladder, the missed doses, the side effect diary: the record a prescriber needs to judge response. Free and private.
Get the app
Why responses differ so much
Response to these medications varies widely between individuals, and nobody can look at you and predict where you will land. Genetics may play a part, but it does not explain the whole range; if it did, the trials would not spread out the way they do.
Outside a trial, the tidy conditions disappear, and ordinary life shapes results. Whether someone tolerates the medication matters, because a rough side effect run can slow a titration a prescriber is guiding. Whether doses are taken as prescribed matters, and not as a moral scorecard: missed doses are an ordinary reality of weekly injections, travel, pharmacy gaps and human weeks, not a character flaw. And whether someone can get the medication consistently matters too, because a supply interruption is not a pause button; the level eases off and has to rebuild.
Notice what all three of those have in common: they are circumstances, several of them temporary, and all of them visible in a log. None of them is a verdict on the person living through them. Any article that treats a missed dose or a rough month as a moral failing is telling you about its authors, not about the medication.
There is also a timing subtlety worth knowing, because appointments do not always line up with the ladder. A follow-up that lands two weeks after a step up is looking at a level that is still climbing, while the same appointment a month later would be looking at one that has settled. Neither date is more virtuous; they are just different vantage points on the same climb. It is one more reason the honest unit of measurement is the whole record rather than whichever month the appointment happened to catch.
What a log actually contributes
When the conversation with a prescriber does happen, "I do not think it is working" is a hard sentence to work with. It has no dates, no doses and no side effect history attached. What a prescriber needs to judge response is specific: where you are on the ladder, how long you have been at each step, which doses were missed, and what side effects did along the way. That is precisely what a tracking log holds.
The dose log shows the ladder position and the gaps. The side effect diary shows whether nausea or fatigue clustered after increases and how severity moved over the weeks, which speaks to tolerance. The weight log shows the trend over the whole arc rather than the last two mornings. None of it argues for anything; all of it replaces memory with record, and record is what a judgment about response can stand on. What a prescriber does with that record is theirs to decide; your part is carrying it into the room intact.
It is worth naming what a log is not, too. It is not evidence for a self-diagnosis of non-response, and it is not ammunition for a case you build before the visit. It is the raw material the two of you look at together, which is a different posture entirely.
What comes next belongs to the prescriber
Here is where honest articles get careful, so this section will be short and plain. Some people who respond weakly to one medication respond differently to a different one. That possibility is real, it is one of the reasons prescribers have options, and it is a decision for the prescriber, made with your history, your tolerance and everything else they know. This article does not recommend switching, and it will not walk through the mechanics of a transition; when that conversation happens, Switching GLP-1 Medications: Tracking Through the Transition covers what changes in a log along the way.
By the same principle, nothing here suggests raising, lowering or stopping anything. The dose ladder you are on was prescribed, the pace of it was prescribed, and the question of whether either should change is a conversation, not a paragraph on a website.
What you can do this week is concrete and small: keep logging, check where you actually are on the ladder before deciding what the last few weeks meant, and if the question is still sitting there at your next appointment, bring the record instead of the worry. The record is shorter, and it does not get defensive when someone asks a follow-up.
Show where you actually areWeeks at each dose step, missed doses, side effects: the whole arc, on your phone and nowhere else.
Download
Frequently asked questions
What counts as not responding to a GLP-1?
Clinicians commonly use a working line of losing less than 5 percent of starting body weight when describing a weaker response, and trials of these medications consistently include a minority of participants below that line. It is a category boundary researchers use, not a verdict on effort, and how many people fall below it varies too much for any single figure to be honest. The judgment that matters is one your prescriber makes with your full history in view.
Can I tell if I am a non-responder before reaching my maintenance dose?
Usually not, and this trips up a lot of people. Starting doses are not weight-loss doses, the titration schedule takes months to climb, and medication levels keep building for about a month after each step up. Judging your response before you have reached the maintenance dose your prescriber prescribed is generally too early. Where you are on the ladder is the first thing to check, not the last.
Why do some people lose less on a GLP-1 than others?
Response varies widely between individuals, and genetics may play a part but does not explain the whole range. Outside the tidy conditions of a trial, ordinary life shapes results too: whether someone tolerates the medication, whether doses are taken as prescribed, and whether they can get their supply consistently. None of these are character judgments. They are circumstances, and several of them can change.
Do missed doses mean my GLP-1 will not work for me?
No, and missed doses are not a moral category. Life interrupts schedules, side effects sometimes slow a titration that a prescriber is guiding, and pharmacy gaps happen. These are ordinary realities, not failures. If doses have been missed, the label's missed-dose rules apply rather than doubling up, and the pattern is worth bringing to your prescriber, who can see the whole picture and decide what, if anything, to do about it.
Should I ask my doctor about switching if I am not responding?
Bring the question to your prescriber, yes, because some people do respond differently to a different medication, and that possibility is exactly the kind a prescriber weighs. But whether and when to switch is a prescriber decision, and this article will not recommend one. What helps the conversation is a log showing where you are on the dose ladder, how long at each step, missed doses and side effects, because response cannot be judged without that context.